Soluble Interleukin 6 Receptor: A Novel Marker of Moderate to Severe Sleep-Related Breathing Disorder | Sleep Medicine | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
He  JKryger  MHZorick  FJConway  WRoth  T Mortality and apnea index in obstructive sleep apnea: experience in 385 male patients.  Chest 1988;949- 14PubMedGoogle ScholarCrossref
2.
Peppard  PEYoung  TPalta  MSkatrud  J Prospective study of the association between sleep-disordered breathing and hypertension.  N Engl J Med 2000;3421378- 1384PubMedGoogle ScholarCrossref
3.
Nieto  FJYoung  TBLind  BK  et al.  Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study.  JAMA 2000;2831829- 1836PubMedGoogle ScholarCrossref
4.
Koskenvuo  MKaprio  JTelakivi  TPartinen  MHeikkila  KSarna  S Snoring as a risk factor for ischaemic heart disease and stroke in men.  Br Med J (Clin Res Ed) 1987;29416- 19PubMedGoogle ScholarCrossref
5.
Marin  JMCarrizo  SJVicente  EAgusti  AG Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.  Lancet 2005;3651046- 1053PubMedGoogle ScholarCrossref
6.
Cusack  MRMarber  MSLambiase  PDBucknall  CARedwood  SR Systemic inflammation in unstable angina is the result of myocardial necrosis.  J Am Coll Cardiol 2002;391917- 1923PubMedGoogle ScholarCrossref
7.
Luc  GBard  JMJuhan-Vague  I  et al.  C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study.  Arterioscler Thromb Vasc Biol 2003;231255- 1261PubMedGoogle ScholarCrossref
8.
Biasucci  LMVitelli  ALiuzzo  G  et al.  Elevated levels of interleukin-6 in unstable angina.  Circulation 1996;94874- 877PubMedGoogle ScholarCrossref
9.
Lindmark  EDiderholm  EWallentin  LSiegbahn  A Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.  JAMA 2001;2862107- 2113PubMedGoogle ScholarCrossref
10.
Huber  SASakkinen  PConze  DHardin  NTracy  R Interleukin-6 exacerbates early atherosclerosis in mice.  Arterioscler Thromb Vasc Biol 1999;192364- 2367PubMedGoogle ScholarCrossref
11.
Ikeda  UIkeda  MOohara  T  et al.  Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner.  Am J Physiol 1991;260H1713- H1717PubMedGoogle Scholar
12.
Le  JMVilcek  J Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response.  Lab Invest 1989;61588- 602PubMedGoogle Scholar
13.
Williams  NBertoncello  IJackson  HArnold  JKavnoudias  H The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production.  Ciba Found Symp 1992;167160- 173PubMedGoogle Scholar
14.
Vgontzas  ANPapanicolaou  DABixler  EOKales  ATyson  KChrousos  GP Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity.  J Clin Endocrinol Metab 1997;821313- 1316PubMedGoogle ScholarCrossref
15.
Yokoe  TMinoguchi  KMatsuo  H  et al.  Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.  Circulation 2003;1071129- 1134PubMedGoogle ScholarCrossref
16.
Kanda  TInoue  MKotajima  N  et al.  Circulating interleukin-6 and interleukin-6 receptors in patients with acute and recent myocardial infarction.  Cardiology 2000;93191- 196PubMedGoogle ScholarCrossref
17.
Yokoyama  AKohno  NSakai  KKondo  KHirasawa  YHiwada  K Circulating levels of soluble interleukin-6 receptor in patients with bronchial asthma.  Am J Respir Crit Care Med 1997;1561688- 1691PubMedGoogle ScholarCrossref
18.
Yokoyama  AKohno  NHirasawa  Y  et al.  Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases.  Clin Exp Immunol 1995;100325- 329PubMedGoogle ScholarCrossref
19.
Rose-John  SHeinrich  PC Soluble receptors for cytokines and growth factors: generation and biological function.  Biochem J 1994;300281- 290PubMedGoogle Scholar
20.
Peters  MMuller  AMRose-John  S Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis.  Blood 1998;923495- 3504PubMedGoogle Scholar
21.
Kallen  KJ The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.  Biochim Biophys Acta 2002;1592323- 343PubMedGoogle ScholarCrossref
22.
Redline  STishler  PVTosteson  TD  et al.  The familial aggregation of obstructive sleep apnea.  Am J Respir Crit Care Med 1995;151682- 687PubMedGoogle ScholarCrossref
23.
Palmer  LJBuxbaum  SGLarkin  E  et al.  A whole-genome scan for obstructive sleep apnea and obesity.  Am J Hum Genet 2003;72340- 350PubMedGoogle ScholarCrossref
24.
Lukaski  HCJohnson  PEBolonchuk  WWLykken  GI Assessment of fat-free mass using bioelectrical impedance measurements of the human body.  Am J Clin Nutr 1985;41810- 817PubMedGoogle Scholar
25.
Rechtschaffen  AedKales  Aed A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects.  Washington, DC US Dept of Health and Human Services1968;NIND publication 204
26.
Redline  SSanders  MHLind  BK  et al.  Methods for obtaining and analyzing unattended polysomnography data for a multicenter study: Sleep Heart Health Research Group.  Sleep 1998;21759- 767PubMedGoogle Scholar
27.
Sleep Disorders Atlas Task Force, EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association.  Sleep 1992;15173- 184PubMedGoogle Scholar
28.
Whitney  CWGottlieb  DJRedline  S  et al.  Reliability of scoring respiratory disturbance indices and sleep staging.  Sleep 1998;21749- 757PubMedGoogle Scholar
29.
Flemons  WWLittner  MRRowley  JA  et al.  Home diagnosis of sleep apnea: a systematic review of the literature: an evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society.  Chest 2003;1241543- 1579PubMedGoogle ScholarCrossref
30.
Johns  MW A new method for measuring daytime sleepiness: the Epworth sleepiness scale.  Sleep 1991;14540- 545PubMedGoogle Scholar
31.
Nissen  SETuzcu  EMSchoenhagen  P  et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.  N Engl J Med 2005;35229- 38PubMedGoogle ScholarCrossref
32.
Imagawa  SYamaguchi  YOgawa  K  et al.  Interleukin-6 and tumor necrosis factor-alpha in patients with obstructive sleep apnea–hypopnea syndrome.  Respiration 2004;7124- 29PubMedGoogle ScholarCrossref
33.
Teramoto  SYamamoto  HOuchi  Y Increased C-reactive protein and increased plasma interleukin-6 may synergistically affect the progression of coronary atherosclerosis in obstructive sleep apnea syndrome.  Circulation 2003;107e40PubMedGoogle ScholarCrossref
34.
Vgontzas  ANChrousos  GP Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders.  Endocrinol Metab Clin North Am 2002;3115- 36PubMedGoogle ScholarCrossref
35.
Carpagnano  GEKharitonov  SAResta  OFoschino-Barbaro  MPGramiccioni  EBarnes  PJ Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients.  Chest 2002;1221162- 1167PubMedGoogle ScholarCrossref
36.
Liu  HLiu  JXiong  SShen  GZhang  ZXu  Y The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome.  J Tongji Med Univ 2000;20200- 202PubMedGoogle ScholarCrossref
37.
Vgontzas  ANPapanicolaou  DABixler  EO  et al.  Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.  J Clin Endocrinol Metab 2000;851151- 1158PubMedGoogle ScholarCrossref
38.
Fried  SKBunkin  DAGreenberg  AS Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid.  J Clin Endocrinol Metab 1998;83847- 850PubMedGoogle Scholar
39.
Mohamed-Ali  VGoodrick  SRawesh  A  et al.  Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.  J Clin Endocrinol Metab 1997;824196- 4200PubMedGoogle Scholar
40.
Yudkin  JSStehouwer  CDEmeis  JJCoppack  SW C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?  Arterioscler Thromb Vasc Biol 1999;19972- 978PubMedGoogle ScholarCrossref
41.
Klouche  MBhakdi  SHemmes  MRose-John  S Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor.  J Immunol 1999;1634583- 4589PubMedGoogle Scholar
42.
Alexandrakis  MGPassam  FHBoula  A  et al.  Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.  Ann Hematol 2003;8219- 23PubMedGoogle Scholar
43.
Romano  MSironi  MToniatti  C  et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.  Immunity 1997;6315- 325PubMedGoogle ScholarCrossref
44.
Hooper  WCPhillips  DJEvatt  BL Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor.  Thromb Haemost 1997;771014- 1019PubMedGoogle Scholar
45.
Ohga  ENagase  TTomita  T  et al.  Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome.  J Appl Physiol 1999;8710- 14PubMedGoogle Scholar
46.
Hasegawa  MSato  SIhn  HTakehara  K Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis.  Rheumatology (Oxford) 1999;38612- 617PubMedGoogle ScholarCrossref
47.
Xu  QBriggs  JPark  S  et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.  Oncogene 2005;245552- 5560PubMedGoogle ScholarCrossref
48.
Castell  JVGeiger  TGross  V  et al.  Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.  Eur J Biochem 1988;177357- 361PubMedGoogle ScholarCrossref
49.
Gerhartz  CDittrich  EStoyan  T  et al.  Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130.  Eur J Biochem 1994;223265- 274PubMedGoogle ScholarCrossref
Original Investigation
September 18, 2006

Soluble Interleukin 6 Receptor: A Novel Marker of Moderate to Severe Sleep-Related Breathing Disorder

Author Affiliations

Author Affiliations: Departments of Medicine (Drs Mehra and Redline) and Pediatrics (Drs Mehra, Kirchner, and Redline, Ms Storfer-Isser, and Mr Johnson), Case School of Medicine, Cleveland, Ohio; and Departments of Biochemistry and Pathology, University of Vermont, Burlington (Drs Jenny and Tracy).

Arch Intern Med. 2006;166(16):1725-1731. doi:10.1001/archinte.166.16.1725
Abstract

Background  Given the previously described association between sleep-related breathing disorder (SRBD) and markers of inflammation, we assessed the relationship of SRBD with levels of both interleukin 6 (IL-6) and soluble IL-6 receptor (sIL-6R), a marker with more expansive physiologic effects than IL-6. The objectives were to explore the relationship between moderate to severe sleep apnea with IL-6 and sIL-6R levels and to examine morning and evening variability for each cytokine.

Methods  A total of 385 adult participants (≥18 years of age) in the Cleveland Family Study, Cleveland, Ohio, underwent sleep studies and determination of IL-6 and sIL-6R levels in samples obtained in the evening and morning of polysomnography. Moderate to severe SRBD was defined as a respiratory disturbance index greater than or equal to 30.

Results  The subjects were aged 44.9 ± 16.7 (mean ± SD) years, 44% were male, and 48% were African American, with a body mass index (weight in kilograms divided by the height in meters squared) of 32.5 ± 8.1 (mean ± SD). Linear regression analysis showed that after adjustment for subject characteristics, waist circumference, and comorbidities, SRBD was not significantly associated with morning IL-6 levels. In contrast, linear regression analyses showed that, compared with the participants without SRBD, those with SRBD had significantly higher morning sIL-6R levels (mean ± SD, 4.60 ± 1.42 ng/mL [P = .001]), even after adjustment for subject characteristics, waist circumference, and comorbidities, which persisted after adjustment of evening sIL-6R levels.

Conclusions  Morning sIL-6R levels demonstrated stronger associations with moderate to severe SRBD than morning IL-6 levels. Associations with SRBD and morning sIL-6R levels persisted even after adjustment for waist circumference, cardiovascular disease, and evening sIL-6R levels, suggesting the potential utility of sIL-6R as a marker for measuring overnight SRBD stresses. Further investigation of this biomarker may provide insight into SRBD-related inflammation.

×